Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
10 09 2022
Historique:
received: 12 08 2021
pubmed: 12 12 2021
medline: 14 9 2022
entrez: 11 12 2021
Statut: ppublish

Résumé

Infective endocarditis (IE) following transcatheter aortic valve replacement (TAVR) has been associated with a dismal prognosis. However, scarce data exist on IE perivalvular extension (PEE) in such patients. This multicenter study included 579 patients who had the diagnosis of definite IE at a median of 171 (53-421) days following TAVR. PEE was defined as the presence of an intracardiac abscess, pseudoaneurysm, or fistula. A total of 105 patients (18.1%) were diagnosed with PEE (perivalvular abscess, pseudoaneurysm, fistula, or a combination in 87, 7, 7, and 4 patients, respectively). A history of chronic kidney disease (adjusted odds ratio [ORadj], 2.08; 95% confidence interval [CI]: 1.27-3.41; P = .003) and IE secondary to coagulase-negative staphylococci (ORadj, 2.71; 95% CI: 1.57-4.69; P < .001) were associated with an increased risk of PEE. Surgery was performed at index IE episode in 34 patients (32.4%) with PEE (vs 15.2% in patients without PEE, P < .001). In-hospital and 2-year mortality rates among PEE-IE patients were 36.5% and 69.4%, respectively. Factors independently associated with an increased mortality were the occurrence of other complications (stroke post-TAVR, acute renal failure, septic shock) and the lack of surgery at index IE hospitalization (padj < 0.05 for all). PEE occurred in about one-fifth of IE post-TAVR patients, with the presence of coagulase-negative staphylococci and chronic kidney disease determining an increased risk. Patients with PEE-IE exhibited high early and late mortality rates, and surgery during IE hospitalization seemed to be associated with better outcomes.

Sections du résumé

BACKGROUND
Infective endocarditis (IE) following transcatheter aortic valve replacement (TAVR) has been associated with a dismal prognosis. However, scarce data exist on IE perivalvular extension (PEE) in such patients.
METHODS
This multicenter study included 579 patients who had the diagnosis of definite IE at a median of 171 (53-421) days following TAVR. PEE was defined as the presence of an intracardiac abscess, pseudoaneurysm, or fistula.
RESULTS
A total of 105 patients (18.1%) were diagnosed with PEE (perivalvular abscess, pseudoaneurysm, fistula, or a combination in 87, 7, 7, and 4 patients, respectively). A history of chronic kidney disease (adjusted odds ratio [ORadj], 2.08; 95% confidence interval [CI]: 1.27-3.41; P = .003) and IE secondary to coagulase-negative staphylococci (ORadj, 2.71; 95% CI: 1.57-4.69; P < .001) were associated with an increased risk of PEE. Surgery was performed at index IE episode in 34 patients (32.4%) with PEE (vs 15.2% in patients without PEE, P < .001). In-hospital and 2-year mortality rates among PEE-IE patients were 36.5% and 69.4%, respectively. Factors independently associated with an increased mortality were the occurrence of other complications (stroke post-TAVR, acute renal failure, septic shock) and the lack of surgery at index IE hospitalization (padj < 0.05 for all).
CONCLUSIONS
PEE occurred in about one-fifth of IE post-TAVR patients, with the presence of coagulase-negative staphylococci and chronic kidney disease determining an increased risk. Patients with PEE-IE exhibited high early and late mortality rates, and surgery during IE hospitalization seemed to be associated with better outcomes.

Identifiants

pubmed: 34894124
pii: 6459521
doi: 10.1093/cid/ciab1004
doi:

Substances chimiques

Coagulase 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

638-646

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Potential conflicts of interest. J. R.-C. has received institutional research grants from Edwards Lifesciences, Medtronic, and Boston Scientific. V. P. has received institutional research grants from Medtronic, Boston Scientific, and Microport. D. T. has received consulting fees from Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Medtronic. H. C. H. has received institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and consulting fees from Edwards Lifesciences and Medtronic. J. G. W. has received consulting fees from Edwards Lifesciences and St. Jude Medical. R. M. has received research grants from Edwards Lifesciences, Medtronic, Abbott, Capricor, and St. Jude Medical; has served as a proctor for Edwards Lifesciences; and has received consulting fees from Medtronic. F. S. de B. has received honoraria from Medtronic and Edwards Lifesciences for symposium speeches and proctoring cases. S. L. has received consulting fees from Edwards Lifesciences. H. Le B. has received lecture fees from Edwards Lifesciences outside the submitted work. J. M. S. has received speaker honoraria from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and research grants from Boston Scientific, Edwards Lifesciences, and Medtronic outside the submitted work. K. W.-K. has received personal fees from Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, and Meril outside the submitted work. S. S. reports grants to their institution from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott and has received personal fees from Boston Scientific, BTG, and Teleflex outside the submitted work. O. H. has received personal fees from Boston Scientific and payments from Abbott. N. M. has received personal fees from Edwards Lifesciences, Medtronic, Biotronik, Novartis, Sanofi Genzyme, AstraZeneca, Pfizer, and Bayer outside the submitted work. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Auteurs

Vassili Panagides (V)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

David Del Val (D)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Mohamed Abdel-Wahab (M)

Heart Center, Leipzig University, Leipzig, Germany.
Heart Center, Segeberger Kliniken, Bad Segeberg, Germany.

Norman Mangner (N)

Heart Center, Leipzig University, Leipzig, Germany.
Herzzentrum Dresden, Technische Universität, Dresden, Germany.

Eric Durand (E)

Normandie Univ, CHU Rouen, Department of Cardiology, Rouen, France.

Nikolaj Ihlemann (N)

Righospitalet, Copenhagen, Denmark.

Marina Urena (M)

Bichat Hôpital, Paris, France.

Costanza Pellegrini (C)

Deutsches Herzzentrum München, Munich, Germany.

Francesco Giannini (F)

Ospedale San Raffaele, Milan, Italy.
Maria Cecilia Hospital, GVM Care and Research, Cotignola RA, Italy.

Tomasz Gasior (T)

Herzzentrum Dresden, Technische Universität, Dresden, Germany.

Wojtek Wojakowski (W)

Medical University of Silesia, Katowice, Poland.

Martin Landt (M)

Heart Center, Segeberger Kliniken, Bad Segeberg, Germany.

Vincent Auffret (V)

Univ Rennes, CHU Rennes, Rennes, France.

Jan Malte Sinning (JM)

Heart Center Bonn, Bonn, Germany.

Asim N Cheema (AN)

St Michaels Hospital, Toronto, Canada.
Southlake Hospital, Newmarket, Ontario, Canada.

Luis Nombela-Franco (L)

Cardiovascular Institute, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.

Chekrallah Chamandi (C)

Hôpital Européen Georges-Pompidou, Paris, France.

Francisco Campelo-Parada (F)

Hôpital Rangueil, Toulouse, France.

Erika Munoz-Garcia (E)

Hospital Universitario Virgen de la Victoria, Malaga, Spain.

Howard C Herrmann (HC)

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Luca Testa (L)

IRCCS Pol. San Donato, Milan, Italy.

Won Keun Kim (WK)

Kerckhoff Heart and Thorax Centre, Bad Nauheim, Germany.

Juan Carlos Castillo (JC)

Hospital Universitario Reina Sofia, Cordoba, Spain.

Alberto Alperi (A)

Hospital Universitario Central de Asturias, Oviedo, Spain.

Didier Tchetche (D)

Clinique Pasteur, Toulouse, France.

Antonio L Bartorelli (AL)

Centro Cardiologico Monzino, IRCCS and Department of Biomedical and Clinical Sciences "Luigi Sacco," University of Milan, Milan, Italy.

Samir Kapadia (S)

Cleveland Clinic, Cleveland, Ohio, USA.

Stefan Stortecky (S)

Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Ignacio Amat-Santos (I)

Hospital Clinico Universitario de Valladolid, Valladolid, Spain.

Harindra C Wijeysundera (HC)

Sunnybrook Health Science Center, Toronto, Canada.

John Lisko (J)

Emory University School of Medicine, Atlanta, Georgia, USA.

Enrique Gutiérrez-Ibanes (E)

Instituto de Investigación Universitaria Gregorio Marañon, Hospital Gregorio Marañon, Madrid, Spain.

Vicenç Serra (V)

Hospital Vall d'Hebron, Barcelona, Spain.

Luisa Salido (L)

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Abdullah Alkhodair (A)

St Paul's Hospital, Vancouver, Canada.

Ugolino Livi (U)

University Hospital of Udine, Udine, Italy.

Tarun Chakravarty (T)

Cedars-Sinai Heart Institute, Los Angeles, California, USA.

Stamatios Lerakis (S)

Emory University School of Medicine, Atlanta, Georgia, USA.
Mount Sinai Hospital, New York, New York, USA.

Victoria Vilalta (V)

Hospital Germans Trias i Pujol, Badalona, Spain.

Ander Regueiro (A)

Hospital Clínic Barcelona, Barcelona, Spain.

Rafael Romaguera (R)

Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Utz Kappert (U)

Herzzentrum Dresden, Technische Universität, Dresden, Germany.

Marco Barbanti (M)

A.O.U. Policlinico Vittorio Emanuele, University of Catania, Catania, Italy.

Jean Bernard Masson (JB)

Centre Hospitalier de l'Université de Montreal, Montreal, Canada.

Frédéric Maes (F)

Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Claudia Fiorina (C)

Spedali Civili di Brescia, Brescia, Italy.

Antonio Miceli (A)

Istituto Clinico Sant'Ambrogio, Milan, Italy.
University Hospital Galway, Galway, Ireland.

Susheel Kodali (S)

Columbia University Medical Center, New York, New York, USA.

Henrique B Ribeiro (HB)

InCor, Heart Institute, University of São Paulo Medical School, Sao Paulo, Brazil.
Hospital Samaritano Paulista, Sao Paulo, Brazil.

Jose Armando Mangione (JA)

Hospital Beneficencia Portuguesa, Sao Paulo, Brazil.

Fabio Sandoli de Brito (F)

InCor, Heart Institute, University of São Paulo Medical School, Sao Paulo, Brazil.

Guglielmo Mario Actis Dato (GM)

Ospedali Mauriziano, Torino, Italy.

Francesco Rosato (F)

Azienda Ospedaliera S. Cocre e Carle, Cuneo, Italy.

Maria Cristina Ferreira (MC)

Hospital Naval Marcilio Dias, Rio de Janeiro, Brazil.

Valter Correia de Lima (V)

Hospital São Francisco-Santa Casa de Porto Alegre, Porto Alegre, Brazil.

Alexandre Siciliano Colafranceschi (AS)

Hospital Pró-cardíaco, Rio de Janeiro, Brazil.

Alexandre Abizaid (A)

InCor, Heart Institute, University of São Paulo Medical School, Sao Paulo, Brazil.

Marcos Antonio Marino (MA)

Hospital Madre Teresa, Belo Horizonte, Brazil.

Vinicius Esteves (V)

Hospital Sao Luiz, Sao Paulo, Brazil.

Julio Andrea (J)

Clínica Sao Vicente, Rio de Janeiro, Brazil.

Roger R Godinho (RR)

Hospital Samaritano Paulista, Sao Paulo, Brazil.

Fernando Alfonso (F)

Hospital Universitario de La Princesa, Madrid, Spain.

Helene Eltchaninoff (H)

Normandie Univ, CHU Rouen, Department of Cardiology, Rouen, France.

Lars Søndergaard (L)

Righospitalet, Copenhagen, Denmark.

Dominique Himbert (D)

Bichat Hôpital, Paris, France.

Oliver Husser (O)

Deutsches Herzzentrum München, Munich, Germany.
St.-Johannes Hospital, Dortmund, Germany.

Azeem Latib (A)

Ospedale San Raffaele, Milan, Italy.
Montefiore Medical Center, New York, New York, USA.

Hervé Le Breton (H)

Univ Rennes, CHU Rennes, Rennes, France.

Clement Servoz (C)

Hôpital Rangueil, Toulouse, France.

Isaac Pascual (I)

Hospital Universitario Central de Asturias, Oviedo, Spain.

Saif Siddiqui (S)

Clinique Pasteur, Toulouse, France.

Paolo Olivares (P)

Centro Cardiologico Monzino, IRCCS and Department of Biomedical and Clinical Sciences "Luigi Sacco," University of Milan, Milan, Italy.

Rosana Hernandez-Antolin (R)

Hospital Universitario Ramón y Cajal, Madrid, Spain.

John G Webb (JG)

St Paul's Hospital, Vancouver, Canada.

Sandro Sponga (S)

University Hospital of Udine, Udine, Italy.

Raj Makkar (R)

Cedars-Sinai Heart Institute, Los Angeles, California, USA.

Annapoorna S Kini (AS)

Mount Sinai Hospital, New York, New York, USA.

Marouane Boukhris (M)

Centre Hospitalier de l'Université de Montreal, Montreal, Canada.

Philippe Gervais (P)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Axel Linke (A)

Heart Center, Leipzig University, Leipzig, Germany.
Herzzentrum Dresden, Technische Universität, Dresden, Germany.

Lisa Crusius (L)

Heart Center, Leipzig University, Leipzig, Germany.
Herzzentrum Dresden, Technische Universität, Dresden, Germany.

David Holzhey (D)

Heart Center, Leipzig University, Leipzig, Germany.

Josep Rodés-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Hospital Clínic Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH